Predictive Toxicology and Screening Group

Michael J. Devito, Ph.D.
Acting Chief, National Toxicology Program Laboratory
Group Leader, Predictive Toxicology and Screening Group

Tel 984-287-4215
michael.devito@nih.gov

111 T W Alexander Dr
Rall Building
Research Triangle Park, NC 27709

Delivery Instructions

Research Summary

Michael DeVito Ph.D., leads the Predictive Toxicology and Screening Group in the NTP Laboratory. The group focuses on developing in vitro assays for use in chemical class characterization and potential high throughput initiatives. Boyd and colleagues work closely with the Biomolecular Screening Branch in a collaborative project that aims to characterize the metabolic capability of the cell lines used in Tox21 and to develop other in vitro approaches that better incorporate metabolism. In addition, this group is focused on translating the results from the high throughput assays in Tox21 for use in chemical class characterization and testing prioritization. Tox21 is a collaboration between several federal agencies to research and test chemicals in a new way using high throughput or rapidly automated approaches to test thousands of chemicals at one time. DeVito is co-chair of the Tox21 targeted testing working.

Initial efforts have focused evaluating the concordance between biological signatures and pathway alterations observed in vitro to biological signatures and pathway alterations in vivo. Recent efforts are focused on the evaluation of in vitro to in vivo extrapolation methods. Projects in the targeted testing group are closely aligned with our Tox21 partners in the National Center for Computational Toxicology at the U.S. Environmental Protection Agency and at the National Center for Advancing Translational Sciences at NIH.